Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event (The Manila Times) - Sep 8, 2026 - "The event will provide an overview of Immunoglobulin G4-Related Disease (IgG4-RD), including current management strategies, and the unmet need of people living with this disease. Management will also provide an update on the Company’s prelaunch preparedness strategies and the potential commercial opportunity for obexelimab for IgG4-RD, if approved by the U.S. Food and Drug Administration (FDA)."
Clinical • Immunology • Inflammation
|